Lupin Evades U.S. Patent Battle With Warner Chilcott For Oral Contraceptives
This article was originally published in PharmAsia News
Executive Summary
WASHINGTON - Indian generic drug maker Lupin may have cleared a big hurdle in its pursuit to launch generic versions of Warner Chilcott's oral contraceptive drugs Loestrin 24 Fe and Femcon in the United States as the Irish company - specializing in dermatology and women's health products - decided to back out from a patent lawsuit it filed at the U.S. District Court of Maryland